ERBB2 and breast cancer: In Li L's study, serum LDH > 244 U / L before the T-DM1 treatment was prognostic risk factors for patients with advanced HER2 positive breast cancer receiving T-DM1 treatment, and LDH uptrend after T-DM1 treatment was also related to the poor prognosis 26.